These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation. Ito Y; Miyamoto T; Kamimura T; Aoki K; Henzan H; Aoki T; Shiratsuchi M; Kato K; Nagafuji K; Ogawa R; Eto T; Iwasaki H; Akashi K Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e47-54. PubMed ID: 25445469 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in the treatment of acute lymphoblastic leukemia. Rafei H; Kantarjian HM; Jabbour EJ Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071 [TBL] [Abstract][Full Text] [Related]
5. [The role of imatinib in the treatment of acute lymphoid leukemias]. Poros A; Lovas N Orv Hetil; 2005 May; 146(18 Suppl 1):905-10. PubMed ID: 15921303 [TBL] [Abstract][Full Text] [Related]
6. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol]. Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166 [TBL] [Abstract][Full Text] [Related]
7. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia. Henze G; v Stackelberg A; Eckert C Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062 [TBL] [Abstract][Full Text] [Related]
10. How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated? Gökbuget N Best Pract Res Clin Haematol; 2017 Sep; 30(3):261-274. PubMed ID: 29050699 [TBL] [Abstract][Full Text] [Related]
11. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia. Ribera JM Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835 [TBL] [Abstract][Full Text] [Related]
14. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018 [TBL] [Abstract][Full Text] [Related]
15. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. Yilmaz M; Kantarjian H; Ravandi-Kashani F; Short NJ; Jabbour E Clin Adv Hematol Oncol; 2018 Mar; 16(3):216-223. PubMed ID: 29742077 [TBL] [Abstract][Full Text] [Related]
16. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ottmann OG; Pfeifer H Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223 [TBL] [Abstract][Full Text] [Related]
17. T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy. Sano H; Mochizuki K; Akaihata M; Kobayashi S; Ohto H; Kikuta A Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27781393 [TBL] [Abstract][Full Text] [Related]
18. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia. Singh N; Frey NV; Grupp SA; Maude SL Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534 [TBL] [Abstract][Full Text] [Related]
19. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. Pieters R; de Groot-Kruseman H; Van der Velden V; Fiocco M; van den Berg H; de Bont E; Egeler RM; Hoogerbrugge P; Kaspers G; Van der Schoot E; De Haas V; Van Dongen J J Clin Oncol; 2016 Aug; 34(22):2591-601. PubMed ID: 27269950 [TBL] [Abstract][Full Text] [Related]
20. Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches. Locatelli F; Moretta F; Rutella S Curr Opin Oncol; 2013 Nov; 25(6):707-15. PubMed ID: 24076579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]